Hos patienter, som fortsatte med behandlingen indtil 5 dage før bypassoperationen, var forekomsten 9, 6% for clopidogrel+ASA og 6, 3% for placebo+ASA.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel+ASA, and 6.3% for placebo+ASA.